Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1013 in secondary hyperparathyroidism in hemodialysis patients
CTR20230421Phase 2Completed
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MT1013 in secondary hyperparathyroidism (SHPT) (9 arms), sponsored by Shaanxi Micot Technology Co., Ltd. Primary endpoint: Treatment-emergent adverse events (TEAEs) incidence. Started Feb 2023; status: completed.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on CTR20230421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230421.